Clinical Trial Update: AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 study comparing Allergan's AGN 201904 to esomeprazole for preventing aspirin-related damage to the stomach and upper intestine in healthy volunteers; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peptic Ulcer

Drugs mentioned

• AGN 201904
• Esomeprazole (Esomeprazole)

Snippet

Sponsor: Allergan | Conditions: Peptic Ulcer | Phase 1 | Status: COMPLETED